VERIPRED 20 Rx
Generic Name and Formulations:
Prednisolone (as sodium phosphate) 20mg/5mL; soln; dye- and alcohol-free; grape-flavor.
Indications for VERIPRED 20:
See literature. Individualize. Initially 5–60mg/day.
See literature. Individualize. Initially 0.14–2mg/kg/day in 3–4 divided doses.
Systemic fungal infections. Live vaccines.
May increase risk and mask signs of infection. Tuberculosis. Latent amebiasis. Strongyloides infestation. Ocular herpes simplex. Cerebral malaria. If exposed to chickenpox or measles, consider prophylaxis with immunoglobulin. Supplement with additional steroids in physiologic stress. Hypertension. Renal insufficiency. CHF. Hypothyroidism. Cirrhosis. Kaposi's sarcoma. Ulcerative colitis if perforation pending. Peptic ulcer. Diverticulitis. Intestinal anastomoses. Myasthenia gravis. Osteoporosis. Diabetes. Avoid abrupt cessation. May cause electrolyte imbalances, adrenocortical insufficiency, psychotic derangements. Use lowest effective dose. Monitor weight, growth, fluid and electrolyte balance, intraocular pressure. Elderly. Pregnancy (Cat.C). Nursing mothers.
Barbiturates, hydantoins, rifampin, ephedrine, other hepatic enzyme inducers may decrease effects. Potentiated by ketoconazole, estrogens (eg, oral contraceptives). Potentiates and potentiated by cyclosporine. Increased risk of GI effects with aspirin or other NSAIDs. Monitor oral anticoagulants. Excretion of salicylates may be increased. Caution with K+ depleting agents (eg, diuretics, amphotericin-B), digoxin, aspirin in hypoprothrombinemia. Withdraw anticholinesterases at least 24 hours before starting steroids. Adjust antidiabetic agents. May suppress reactions to skin tests.
HPA axis suppression, increased susceptibility to infection, glaucoma, cataracts, secondary infections, hypokalemia, hypocalcemia, hypernatremia, hypertension, CHF, psychic disorders, myopathy, osteoporosis, peptic ulcer, dermal atrophy, increased intracranial pressure, carbohydrate intolerance.
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Chronic Spinal Pain and Depression: Does One Represent a Risk Factor for the Other?
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- Persistence of Post-Traumatic CRPS Associated With Initial Pain Sensitization
- Comparable Incidence, Intensity of Tourniquet Pain With Infraclavicular, Axillary Brachial Plexus Blocks
- Many Patients Withhold Information From Clinicians
- Shifting Pattern Seen for Primary Care Office Visits
- Questionnaire Reliably Predicts Effect of Migraine on Work-Related Duties
- Clinicians Must Do Their Part to Address Inaccurate Online Health Information